Olaparib

Drug Profile

Olaparib

Alternative Names: AZD 221; AZD-2281; KU-0059436; KU-59436; Lynparza

Latest Information Update: 20 Jul 2017

Price : $50

At a glance

  • Originator KuDOS Pharmaceuticals
  • Developer AstraZeneca; Cancer Research UK; Dana-Farber Cancer Institute; Eli Lilly; European Network of Gynaecological Oncological Trial Groups; German Breast Group; M. D. Anderson Cancer Center; Massachusetts General Hospital; Myriad Genetics; National Cancer Institute (USA); National Institute of Oncology; Netherlands Cancer Institute; NHS Greater Glasgow and Clyde; University of Oxford; University of Texas M. D. Anderson Cancer Center
  • Class Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Phthalazines; Piperazines; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ovarian cancer
  • Phase III Breast cancer; Pancreatic cancer; Prostate cancer
  • Phase II Gastric cancer; Solid tumours
  • Phase I/II Fallopian tube cancer; Glioblastoma; Head and neck cancer; Peritoneal cancer; Small cell lung cancer
  • Phase 0 Endometrial cancer
  • No development reported Colorectal cancer

Most Recent Events

  • 18 Jul 2017 AstraZeneca plans a phase I trial in Solid tumours (In children, In adolescents, Late-stage disease, Second-line therapy or greater) in Japan (PO) (UMIN000025521)
  • 10 Jul 2017 AstraZeneca announces intention to submit regulatory application for Breast cancer (Metastatic disease, gBRCA positive) in European Union in 2018 (AstraZeneca pipeline, July 2017)
  • 10 Jul 2017 AstraZeneca announces intention to submit regulatory application for Ovarian cancer (gBRCA positive, platinum sensitive, Second-line therapy or greater) in USA in 2018 (AstraZeneca pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top